跳至主要内容
临床试验/NCT03932123
NCT03932123招募中不适用

Efficacy and Safety of Antibiotics in the Treatment of Early Onset Neonatal Sepsis

Shandong University1 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2019年5月5日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
500
试验地点
1
主要终点
Treatment failure

研究概览

简要总结

Antibiotic therapy for early onset neonatal sepsis recommended by international guidelines and relevant studies is only kind of treatment regimen that penicillin G/ penicillin/ampicillin combined with gentamicin as the first-line treatment regimen. However, it is not applicable to the clinical practice in many countries and regions. We aim to study efficacy and safety of antibiotics in the treatment of early onset neonatal sepsis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
0 Days 至 3 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Age: postnatal age ≤ 72h;
  • Meets NICE guidelines for using antibiotics to treat EONS;
  • Azlocillin used as part of antimicrobial treatment;
  • Parental written consent.

排除标准

  • Expected survival time less than the treatment cycle;
  • Major congenital malformations;
  • Undergoing surgery within the first week of life;
  • Receiving other systemic trial drug therapy;
  • Other factors that the researcher considers unsuitable for inclusion.

结局指标

主要结局

Treatment failure

时间窗: 72 hours after ending initial antibiotic therapy

* requiring additional courses of antibiotic therapy within 72 hours after ending initial antibiotic therapy and/or * progression of the illness, necessitating a change of antibiotic and/or * blood culture isolate reported resistant to the antibiotic.

次要结局

  • Treatment duration(Through study completion, an average of 3 days)
  • Duration of hospitalization(In the first month of patients' life)
  • White blood cell count(Through study completion, an average of 3 days)
  • C-reactive protein(Through study completion, an average of 3 days)
  • PD target(Through study completion, an average of 3 days)
  • Procalcitonin(Through study completion, an average of 3 days)
  • Death(In the first month of patients' life)
  • Adverse events(Through study completion, an average of 3 days)

研究者

发起方
Shandong University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Wei Zhao

Head of department of clinical pharmacy and pharmacology

Shandong University

研究点 (1)

Loading locations...

相似试验